NKGen Biotech, Inc.

NasdaqGM:NKGN Stock Report

Market Cap: US$23.8m

NKGen Biotech Management

Management criteria checks 1/4

NKGen Biotech's CEO is Paul Y. Song, appointed in Sep 2023, has a tenure of 1.42 years. total yearly compensation is $3.33M, comprised of 15% salary and 85% bonuses, including company stock and options. directly owns 0.38% of the company’s shares, worth $90.26K. The average tenure of the management team and the board of directors is 1.4 years and 1.4 years respectively.

Key information

Paul Y. Song

Chief executive officer

US$3.3m

Total compensation

CEO salary percentage15.0%
CEO tenure1.4yrs
CEO ownership0.4%
Management average tenure1.4yrs
Board average tenure1.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Paul Y. Song's remuneration changed compared to NKGen Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$88m

Mar 31 2024n/an/a

-US$80m

Dec 31 2023US$3mUS$500k

-US$83m

Sep 30 2023n/an/a

-US$56m

Jun 30 2023n/an/a

-US$30m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$37mUS$366k

-US$27m

Compensation vs Market: Paul Y.'s total compensation ($USD3.33M) is above average for companies of similar size in the US market ($USD637.96K).

Compensation vs Earnings: Paul Y.'s compensation has been consistent with company performance over the past year.

CEO

Paul Y. Song (58 yo)

1.4yrs

Tenure

US$3,328,322

Compensation

Dr. Paul Y. Song, M.D. joined Calyx Peak Of Ma, Inc. as Chief Medical Officer in 2017. Dr. Song, a board-certified radiation oncologist in Los Angeles and a partnership was formed. He was a Co-Founder & Ch...

Leadership Team

NamePositionTenureCompensationOwnership
Paul Y. Song
CEO & Chairman1.4yrsUS$3.33m0.38%
$ 90.3k
Yong Man Kim
Chief Scientific Officer1.4yrsUS$809.26k0.063%
$ 15.0k
James Graf
Interim Chief Financial Officer1.4yrsno data4.65%
$ 1.1m
Yoonmi Kang
SVP of Technical Ops & Developmentno datano datano data
Irene Chang
SVP, HR & Corporate Cultureno datano datano data
Denise Chua
SVP of Corporate Affairsless than a yearno datano data
Ryan Park
EVP of Financial Planning & Analysis and Corporate Strategy1.3yrsno datano data

1.4yrs

Average Tenure

59yo

Average Age

Experienced Management: NKGN's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Paul Y. Song
CEO & Chairmanless than a yearUS$3.33m0.38%
$ 90.3k
Michael Klowden
Independent Director1.4yrsno data0%
$ 0
Kathleen Scott
Independent Director1.4yrsno data0%
$ 0
Anthony Reder
Member of Scientific Advisory Board1.9yrsno datano data
Evren Alici
Member of Scientific Advisory Boardno datano datano data
Craig Blackstone
Member of Scientific Advisory Board1.9yrsno datano data
Marco Gottardis
Independent Directorless than a yearno data0%
$ 0
Ming Guo
Member of Scientific Advisory Board1.9yrsno datano data

1.4yrs

Average Tenure

66yo

Average Age

Experienced Board: NKGN's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/19 11:54
End of Day Share Price 2025/02/19 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NKGen Biotech, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.